Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 1.4.3.13 extracted from

  • De Vita, A.; Liverani, C.; Molinaro, R.; Martinez, J.O.; Hartman, K.A.; Spadazzi, C.; Miserocchi, G.; Taraballi, F.; Evangelopoulos, M.; Pieri, F.; Bongiovanni, A.; Mercatali, L.; Tasciotti, E.; Ibrahim, T.
    Lysyl oxidase engineered lipid nanovesicles for the treatment of triple negative breast cancer (2021), Sci. Rep., 11, 5107 .
    View publication on PubMedView publication on EuropePMC
Search for more literature for 1.4.3.13

Application

Application Comment Organism
medicine an extracellular matrix (ECM)-targeting nanotherapeutic is engineered using a lipid-based nanoparticle chemically linked to an inhibitor of the ECM-related enzyme, lysyl oxidase 1 (LOX), that inhibits the crosslinking of elastin and collagen fibers. When the conjugated vesicles are loaded with the chemotherapeutic epirubicin, superior inhibition of triple negative breast cancer (TNBC) cell growth is observed both in vitro and in vivo Homo sapiens

Organism

Organism UniProt Comment Textmining
Homo sapiens Q08397
-
-

Synonyms

Synonyms Comment Organism
lysyl oxidase 1
-
 Homo sapiens